<DOC>
	<DOC>NCT02861014</DOC>
	<brief_summary>The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.</brief_summary>
	<brief_title>A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria Have a length of disease duration, from first symptom, of less than (&lt;) 10 years Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy Suboptimal disease control while on a DMT Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 6 months after the last dose of study drug Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS) Inability to complete an Magnetic Resonance Imaging (MRI) procedure Known presence of other neurological disorders Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study History or currently active primary or secondary immunodeficiency History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies History of opportunistic infections History or known presence of recurrent or chronic infection History of malignancy Congestive heart failure Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>